Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The index has shown a price loss of -13.89% this year. Over the last six months, there has been a stronger performance of -73.48%. The price of EVAX leaped by -18.21% during the last 30 days period. For the last 5-days stocks have improved 10.64%.
In terms of market performance, Evaxion Biotech A/S ADR had a somewhat inconsistent run in. The highest value for the stock in the past year was $68.05 on 01/24/24, while the lowest value was $2.38 on 01/22/25.
52-week price history of EVAX Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Evaxion Biotech A/S ADR’s current trading price is -94.65% away from its 52-week high, while its distance from the 52-week low is 52.94%. The stock’s price range for this period has been between $2.38 and $68.05. The Healthcare sector company’s shares saw a trading volume of about 3.6 million for the day, which was higher than the average daily volume of 90450.0 over the last three months.
The Connection Between Financial Performance and Market Capitalization
Evaxion Biotech A/S ADR (EVAX) has experienced a quarterly decline of -71.34% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.93M and boasts a workforce of 49 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.27, with a change in price of -11.41. Similarly, Evaxion Biotech A/S ADR recorded 101,461 in trading volume during the last 100 days, posting a change of -75.81%.
EVAX’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for EVAX stands at 149.86. Similarly, the long-term debt-to-equity ratio is also 143.00.
EVAX Stock Stochastic Average
As of today, the raw stochastic average of Evaxion Biotech A/S ADR over the last 50 days is at 11.70%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 33.87%. Further, the company’s Stochastic %K and %D values for the last 20 days were 12.90% and 5.80%, respectively.
